Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ciba Tinosorb sunscreens

This article was originally published in The Tan Sheet

Executive Summary

Ciba Specialty Chemicals should initiate NDA process for UVA/UVB filters Tinosorb M and Tinosorb S to obtain approval as OTC sunscreens, FDA says in July 15 letter denying Ciba's May 21 "time and extent" application to introduce ingredients in the U.S. based on foreign marketing experience. Ciba has "not demonstrated that the ingredients have been marketed for a material time and a material extent," FDA says, noting ingredients must be marketed for a "minimum of five continuous years in the same country and in sufficient quantity." Ciba has only provided two-and-a-half years of continuous use data. TEA was adapted from petition filed by the company Sept. 5, 2000 seeking monograph status for ingredients (1"The Tan Sheet" Sept. 11, 2000, p. 9). FDA decision appears to be first denial of a TEA...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel